Table 1.

Baseline characteristics by AKI status in the study cohorts

Clinical VariableCoronavirus Disease 2019Influenza
No AKI (n=219)AKI (n=106)P valueNo AKI (n=290)AKI (n=143)P value
Age (yr)62 (47–75)67 (57–81)0.0172 (59–85)73 (60–84)0.5
Female111 (51)47 (44)0.3180 (62)81 (57)0.3
Race 0.0060.02
 Black99 (45)68 (64)58 (20)46 (32)
 Non-Hispanic white86 (39)28 (26)221 (76)92 (64)
 Hispanic/other34 (16)10 (9)11 (4)5 (4)
Primary payor <0.00010.09
 Medicare110 (50)76 (72)215 (74)116 (81)
 Medicaid38 (17)13 (12)32 (11)17 (12)
 Managed care71 (32)15 (14)41 (14)9 (6)
 Other02 (2)2 (0.7)1 (0.7)
BMI, kg/m2 31.2 (26.3–36.1)28.6 (24.4–37.1)0.9927.9 (23.9–33.8)29.6 (24.7–34.9)0.2
Residence on admit 0.030.07
 Home177 (81)74 (70)261 (90)120 (84)
 Other42 (19)32 (30)29 (10)23 (16)
Diabetes mellitus71 (37)56 (58)0.000587 (33)56 (42)0.07
Hypertension96 (50)60 (63)0.04165 (62)93 (69)0.1
Heart failure34 (18)35 (37)0.000460 (22)52 (39)0.0005
CAD31 (16)26 (27)0.0376 (28)41 (31)0.6
PVD14 (7)8 (8)0.730 (11)15 (11)1
COPD33 (17)18 (19)0.7103 (38)48 (36)0.6
Asthma33 (17)22 (23)0.286 (32)41 (31)0.8
CKD25 (13)52 (54)<0.000144 (16)76 (56)<0.0001
Comorbidity count 0.00010.009
 0–198 (51)30 (31)98 (37)33 (24)
 2–365 (34)31 (32)91 (34)43 (32)
 4+30 (16)35 (37)79 (30)59 (44)
RAAS medications74 (34)53 (50)0.005121 (42)71 (50)0.1
Immunosuppression24 (11)14 (13)0.6131 (45)66 (46)0.8
Neutrophil/lymphocyte ratio4.2 (2.6–8.4)4.5 (2.9–8.1)0.27.2 (4.0–13.6)6.8 (4.0–11.2)0.9
Baseline sCr (mg/dl)0.8 (0.7–1.0)1.0 (0.9–1.2)<0.00010.8 (0.7–1.0)1.0 (0.8–1.2)<0.0001
  • Data are presented as median (IQR) or number (%). BMI, body mass index; CAD, coronary artery disease; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; RAAS, renin angiotensin aldosterone system; sCr, serum creatinine.